Antibody Therapeutics and Blood Antibody Therapeutics Market

Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.

Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.
Antibody Therapeutics and Blood Antibody Therapeutics Market contains market size and forecasts of Antibody Therapeutics and Blood Antibody Therapeutics in Global, including the following market information:
Global Antibody Therapeutics and Blood Antibody Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Antibody Therapeutics and Blood Antibody Therapeutics market was valued at 196950 million in 2021 and is projected to reach US$ 371150 million by 2028, at a CAGR of 9.5% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
IgG1 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Antibody Therapeutics and Blood Antibody Therapeutics include Roche, Abbvie, Johnson & Johnson, Bristol-Myers Squibb, Novartis, Merck, Alexion Pharmaceuticals, Takeda and Amgen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Antibody Therapeutics and Blood Antibody Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antibody Therapeutics and Blood Antibody Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Antibody Therapeutics and Blood Antibody Therapeutics Market Segment Percentages, by Type, 2021 (%)
IgG1
IgG4
Others
Global Antibody Therapeutics and Blood Antibody Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Antibody Therapeutics and Blood Antibody Therapeutics Market Segment Percentages, by Application, 2021 (%)
Autoimmune
Tumor
Others
Global Antibody Therapeutics and Blood Antibody Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Antibody Therapeutics and Blood Antibody Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Antibody Therapeutics and Blood Antibody Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Antibody Therapeutics and Blood Antibody Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Abbvie
Johnson & Johnson
Bristol-Myers Squibb
Novartis
Merck
Alexion Pharmaceuticals
Takeda
Amgen
Biogen
UCB
Eli Lilly and Company
AstraZeneca